Natural HPV immunity and vaccination strategies

被引：37

作者：

Stern, PL ^{[1
]}

Brown, M

Stacey, SN

Kitchener, HC

Hampson, I

Abdel-Hady, E

Moore, JV

机构：

[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Immunol, Manchester M20 4BX, Lancs, England

[2] Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Mol Biol, Manchester M20 4BX, Lancs, England

[3] Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Radiat Oncol, Manchester M20 4BX, Lancs, England

[4] Univ Manchester, St Marys Hosp, Acad Dept Obstet & Gynaecol & Reprod Hlth Care, Manchester M13 0JH, Lancs, England

来源：

JOURNAL OF CLINICAL VIROLOGY | 2000年 / 19卷 / 1-2期

关键词：

human papillomavirus (HPV); vaccines; prophylaxis and therapy; vulval intraepithelial neoplasia;

D O I：

10.1016/S1386-6532(00)00128-1

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: the task of preventing premature death in women map be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia. (C) 2000 Elsevier Science B.V. All rights reserved.

引用

页码：57 / 66

页数：10

共 71 条

[1] ABDELHADY ES, 2000, UNPUB LANCET
[2] Af Geijersstam V, 1999, INT J CANCER, V80, P489, DOI 10.1002/(SICI)1097-0215(19990209)80:4<489::AID-IJC1>3.0.CO
[3] 2-9
[4] Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO
[5] 2-K
[6] Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions
Arany, I
Tyring, SK
[J]. SEXUALLY TRANSMITTED DISEASES, 1996, 23 (06) : 475 - 480
[7] The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α
Barnard, P
McMillan, NAJ
[J]. VIROLOGY, 1999, 259 (02) : 305 - 313
[8] Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia II. Systemic but not local IgA responses correlate with clearance of HPV-16
Bontkes, HJ
de Gruijl, TD
Walboomers, JMM
Schiller, JT
Dillner, J
Helmerhorst, TJM
Verheijen, RHM
Scheper, RJ
Meijer, CJLM
[J]. JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 409 - 417
[9] Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression
Bontkes, HJ
Walboomers, JMM
Meijer, CJLM
Helmerhorst, TJM
Stern, PL
[J]. LANCET, 1998, 351 (9097) : 187 - 188
[10] Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
Bontkes, HJ
de Gruijl, TD
Bijl, A
Verheijen, RHM
Meijer, CJLM
Scheper, RJ
Stern, PL
Burns, JE
Maitland, NJ
Walboomers, JMM
[J]. JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 2453 - 2459

← 1 2 3 4 5 6 7 8 →